Slide 1: AngioDynamics First Quarter 2020 Earnings Presentation
AngioDynamics First Quarter 2020 Earnings Presentation October 3, 2019 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, c
Slide 3: First Quarter FY2020 Highlights
First Quarter FY2020 Highlights Financial Performance Product Family Year-over-Year Sales Growth Q1 FY20 Q1 FY19 Change Vascular Interventions and Therapies (in millions) Revenue $66.0 $63.9 3.3% AngioVac® 33% Thrombolytic 16% Organic Revenue $62.9 $63.6 (1.0%) Core Peripheral (1%) Revenue Excluding
Slide 4: First Quarter FY2020 Results (unaudited)
First Quarter FY2020 Results (unaudited) FY2020 FY2019 $ in thousands (except per share data) Q1 Results Q1 Results Change Revenue $66,042 $63,943 3.3% Vascular Interventions and Therapies 28,913 28,598 1.1% Vascular Access 23,159 23,790 (2.7%) Oncology 13,970 11,555 20.9% United States 52,937 51,49
Slide 5: Balance Sheet Position
Balance Sheet Position Use of Cash in Q1 FY20 New Credit Facility (in millions) (in millions) Cash at May 31, 2019 $227.6 Debt at May 31, 2019 $132.5 Pay down Credit Facility (132.5) Pay down Credit Facility (132.5) Variable Compensation Payment* (8.7) Draw on Revolver 0.0 Third Party Closing Costs
Slide 6: FY2020 Guidance
FY2020 Guidance Previous Guidance Current Guidance Revenue $280 - $286m $280 - $286m Adjusted EPS $0.25 - $0.30 $0.10 - $0.15* Gross Margin 58% - 59% 58% - 59% * Current guidance to account for investments related to a full-market launch of the products acquired from Eximo Medical Ltd. 6
Slide 7: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 7
Slide 8: Reconciliation of GAAP to Non-GAAP Net Income and EPS
Reconciliation of GAAP to Non-GAAP Net Income and EPS Amounts in thousands (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. (2) Deferred financing fees related to the o
Slide 9: Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS
Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS Amounts in thousands 9
Slide 10: Growth through Focus Execution Accountability
Growth through Focus Execution Accountability 10